期刊文献+

砷制剂抗淋巴瘤作用研究进展

Anti-lymphoma effect of arsenic preparations:research advances
下载PDF
导出
摘要 砷最早被认为是有毒物质,譬如,三氧化二砷(砒霜)有剧毒,但近年来,砷化合物在肿瘤治疗方面发挥着重要的作用。许多研究表明,砷制剂抗肿瘤作用广泛,在治疗白血病方面疗效尤为显著,但对淋巴瘤的治疗研究较少。本文对砷制剂抗淋巴瘤研究进展及作用机制进行综述,以期为更多的砷制剂治疗淋巴瘤相关研究提供参考。 Arsenic was originally regarded as a toxic substance.For example,arsenic trioxide is highly toxic.But in recent years,arsenic compounds have played an important role in cancer treatment.Many studies have shown that arsenic preparations have a wide range of anti-tumor effects,especially with the significant effect seen in the treatment of leukemia.However,there have been few studies on the therapeutic effect of arsenic preparations on lymphoma so far.This paper reviews the research progress in the antilymphoma effect and related action mechanism of arsenic preparations,so as to provide a reference for further studies on the lymphoma treatment with arsenic preparations.
作者 李旭 姜爽 樊磊 张英杰 史丹 王晓波 LI Xu;JIANG Shuang;FAN Lei;ZHANG Ying-jie;SHI Dan;WANG Xiao-bo(Dalian Medical University,Dalian 116044,China;Department of Pharmacy,The 967th Hospital of Joint Logistics Force,Dalian 116021,China)
出处 《国际药学研究杂志》 CAS 北大核心 2020年第4期258-262,共5页 Journal of International Pharmaceutical Research
基金 中国医药教育协会科学技术研究面上资助项目(2016SKT-M010)。
关键词 砷制剂 淋巴瘤 抗淋巴瘤作用机制 arsenic preparation lymphoma anti-lymphoma mechanism
  • 相关文献

参考文献2

二级参考文献24

  • 1黄勇,杨宁蓉,秦叔逵.三氧化二砷注射液治疗难治性非霍奇金淋巴瘤[J].临床肿瘤学杂志,2004,9(6):635-636. 被引量:8
  • 2王京华,李晓云,董敏,戴海滨,关悦,刘芳,张延清,张剑,郭博,刘娟,陈曦,刘娜,苏雁华,王孟学,王芝琪.三氧化二砷隔日给药治疗急性早幼粒细胞白血病的临床观察[J].中华血液学杂志,2005,26(8):507-508. 被引量:3
  • 3侯淑玲,张巧花,王军,贺建霞,郑玉萍.三氧化二砷(As_2O_3)治疗难治性恶性淋巴瘤近期疗效[J].中国肿瘤临床,2005,32(24):1425-1426. 被引量:5
  • 4陶丽菊,王小超,陈诗强,揭旭日.三氧化二砷注射液治疗难治性非霍奇金淋巴瘤疗效观察[J].右江医学,2006,34(6):628-629. 被引量:1
  • 5Liu B, Pan S, Dong X, et al. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice [J]. Cancer Sci, 2006,97(7) :675-81.
  • 6Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: comparison with conventional dosage [J~. Leukemia, 2001,15(5):735-741.
  • 7Schiller GJ, Slack J, Hainsworth JD, et al. Phase Ⅱ multicenter study of arsenic trioxide in patients with myelodysplastic syndromes [ J ]. J Clin Oncol, 2006,24 (16) : 2456-2464.
  • 8Huilgol NG. A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer [ J ]. Int J Hyperthermia, 2006,22 ( 5 ) : 391-397.
  • 9Hermine O, Dombret H, Poupon J, et al. Phase Ⅱ trial of arsenic trioxide and alpha interferon in patients with relapsed/ refractory adult T-cell leukemia/lymphoma [J]. Hematol J, 2004,5(2) : 130-134.
  • 10Michel L, Dupuy A, Jean-Louis F, et al. Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C) [J]. J Invest Dermatol, 2003,121 (4) : 881-893.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部